IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
© 2023. Springer Nature Limited..
Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammatory bowel disease. Upon their secretion by antigen-presenting cells, they exert both pro-inflammatory and anti-inflammatory receptor-mediated effects. An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab), or the IL-23-specific subunit (p19; targeted by risankizumab, guselkumab, brazikumab and mirikizumab). This Review provides a summary of the biology of the IL-12 family cytokines IL-12 and IL-23, discusses the role of these cytokines in intestinal homeostasis and inflammation, and highlights IL-12- and IL-23-directed drug development for the treatment of Crohn's disease and ulcerative colitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Nature reviews. Gastroenterology & hepatology - 20(2023), 7 vom: 07. Juli, Seite 433-446 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verstockt, Bram [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
187348-17-0 |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41575-023-00768-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355732610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355732610 | ||
| 003 | DE-627 | ||
| 005 | 20240326234809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41575-023-00768-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM355732610 | ||
| 035 | |a (NLM)37069321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verstockt, Bram |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-12 and IL-23 pathway inhibition in inflammatory bowel disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammatory bowel disease. Upon their secretion by antigen-presenting cells, they exert both pro-inflammatory and anti-inflammatory receptor-mediated effects. An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab), or the IL-23-specific subunit (p19; targeted by risankizumab, guselkumab, brazikumab and mirikizumab). This Review provides a summary of the biology of the IL-12 family cytokines IL-12 and IL-23, discusses the role of these cytokines in intestinal homeostasis and inflammation, and highlights IL-12- and IL-23-directed drug development for the treatment of Crohn's disease and ulcerative colitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Interleukin-12 |2 NLM | |
| 650 | 7 | |a 187348-17-0 |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 650 | 7 | |a Interleukin-23 |2 NLM | |
| 700 | 1 | |a Salas, Azucena |e verfasserin |4 aut | |
| 700 | 1 | |a Sands, Bruce E |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Leibovitzh, Haim |e verfasserin |4 aut | |
| 700 | 1 | |a Neurath, Markus F |e verfasserin |4 aut | |
| 700 | 1 | |a Vande Casteele, Niels |e verfasserin |4 aut | |
| 700 | 0 | |a Alimentiv Translational Research Consortium (ATRC) |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, Silvio |e investigator |4 oth | |
| 700 | 1 | |a D'Haens, Geert |e investigator |4 oth | |
| 700 | 1 | |a Eckmann, Lars |e investigator |4 oth | |
| 700 | 1 | |a Faubion, William A |e investigator |4 oth | |
| 700 | 1 | |a Feagan, Brian G |e investigator |4 oth | |
| 700 | 1 | |a Jairath, Vipul |e investigator |4 oth | |
| 700 | 1 | |a Ma, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Mehandru, Saurabh |e investigator |4 oth | |
| 700 | 1 | |a Panes, Julian |e investigator |4 oth | |
| 700 | 1 | |a Rieder, Florian |e investigator |4 oth | |
| 700 | 1 | |a Sandborn, William J |e investigator |4 oth | |
| 700 | 1 | |a Silverberg, Mark S |e investigator |4 oth | |
| 700 | 1 | |a Veny, Marisol |e investigator |4 oth | |
| 700 | 1 | |a Vermeire, Severine |e investigator |4 oth | |
| 700 | 1 | |a Vetrano, Stefania |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Gastroenterology & hepatology |d 2009 |g 20(2023), 7 vom: 07. Juli, Seite 433-446 |w (DE-627)NLM187650985 |x 1759-5053 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:7 |g day:07 |g month:07 |g pages:433-446 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41575-023-00768-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 7 |b 07 |c 07 |h 433-446 | ||